<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28825" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Biochemistry, Secondary Protein Structure</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rehman</surname>
            <given-names>Ibraheem</given-names>
          </name>
          <aff>Cornell University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Farooq</surname>
            <given-names>Mustafa</given-names>
          </name>
          <aff>Medical College of Georgia at Augusta University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Botelho</surname>
            <given-names>Salome</given-names>
          </name>
          <aff>Stanford University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ibraheem Rehman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mustafa Farooq declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Salome Botelho declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>11</day>
          <month>12</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28825.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Nearly every function in living beings depends on proteins. They account for 50% of the dry mass of cells and play a role in everything an organism does. There are many different types of proteins. Different proteins can play a role in speeding up chemical reactions, storage, defense, cell communication, movement, and structural support. Humans have tens of thousands of proteins in their bodies at any moment. Each of these proteins has its structure and function. They are known as the most structurally complicated biological molecules. As diverse as they can be, they are all made up of the same 20 amino acids. Large polypeptide chains can be created by forming peptide bonds between the amino and carboxyl groups on&#x000a0;2 different amino acids.<xref ref-type="bibr" rid="article-28825.r1">[1]</xref>&#x000a0;Every protein can be described according to its primary, secondary, tertiary, and quaternary structures. In brief, the primary structure is the linear chain of amino acids. The secondary structure comprises regions stabilized by hydrogen bonds between atoms in the polypeptide backbone. Tertiary structure is the protein's 3-dimensional shape determined by regions stabilized by interactions between the side chains. Quaternary structure is the association between&#x000a0;2 or more polypeptides, but not every protein has a quaternary structure.<xref ref-type="bibr" rid="article-28825.r2">[2]</xref><xref ref-type="bibr" rid="article-28825.r3">[3]</xref></p>
      </sec>
      <sec id="article-28825.s2" sec-type="Fundamentals">
        <title>Fundamentals</title>
        <p>The secondary structure arises from the hydrogen bonds formed between atoms of the polypeptide backbone. Hydrogen bonds form between the partially negative oxygen and partially positive nitrogen atoms. It is significant to point out that the only hydrogen bonds involved in secondary structure do not include any involving amino acid side chains. Most proteins have segments of their polypeptide chains that are either coiled or folded in patterns that contribute to the protein&#x02019;s shape. Many of these coils and folds repeat so often that they have been given names. Two extremely common folds in biochemistry are the alpha-helix and the beta-pleated sheet. The alpha-helix is a right-handed helical coil held together by hydrogen bonding between every fourth amino acid. Many globular proteins have multiple alpha-helical portions separated by long stretches of non-helical regions. Some fibrous proteins, including alpha-keratin, are almost completely comprised of alpha-helices. Fingernails and toenails are also made up of alpha-helices. Transmembrane proteins contain alpha-helices with specific hydrophobic properties, allowing them to traverse membranes and be stable within the cell membrane. Outside the membrane, the transmembrane proteins adopt a non-helical structure, and often, the alpha-helix is broken by a proline residue.</p>
        <p>The other common secondary structure is the beta-pleated sheet. In this structure,&#x000a0;2 different regions of a polypeptide chain lie side by side and are bound by hydrogen bonds. They make up the core of many globular proteins. The&#x000a0;2 types of beta-pleated sheets are parallel beta-pleated sheets and antiparallel beta-pleated sheets. The end of a polypeptide chain can either be the N-terminus or the C-terminus. The N-terminus is the end that contains the free amino group, and the C-terminus is the end that contains the free carboxyl group. If&#x000a0;2 beta-strands run in the same direction, then it is a parallel beta-pleated sheet, and if they run in opposing directions, then it is an antiparallel beta-pleated sheet. Another less commonly known secondary structure is the beta-barrel. This structure is composed of antiparallel beta-strands, and it is twisted and coiled into a barrel so that the first strand hydrogen bonds to the last strand. Many times, beta-barrels can be found in proteins that span the membrane. One common example is aquaporins, which selectively allow water molecules in and out of a cell while preventing the passage of other solutes and ions. Also, it is important to note that the hydrogen bonds between the binding atoms are weak, but the summation of all the hydrogen bonds allows the structure to maintain its shape.</p>
      </sec>
      <sec id="article-28825.s3" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Changes in protein structure can lead to a variety of diseases. The secondary structure of a protein can be altered by either a mutation in the primary sequence of amino acids that make up the protein or by extreme conditions that force the proteins to denature or lose their shape. Prion diseases, spongiform encephalopathies, and Amyloidosis are&#x000a0;2 classes of diseases involving changes in the secondary structure of proteins. Both involve the misfolding of proteins into Beta sheets, and the presence of these proteins leads to tissue damage. If even&#x000a0;1 amino acid is changed in the primary sequence of a protein, the secondary structure of a protein can be drastically affected. Most genetic diseases can be linked to a protein that does not have the structure it should be. One such genetic disease is sickle-cell disease, in which&#x000a0;1 glutamic acid amino acid is replaced with a valine amino acid.<xref ref-type="bibr" rid="article-28825.r4">[4]</xref></p>
        <p>
<bold>Spongiform Encephalopathies</bold>
</p>
        <p>Four spongiform encephalopathies to be aware of are Creutzfeldt-Jakob disease, variant Creutzfeldt-Jakob disease due to bovine spongiform encephalopathy, Kuru, and fatal familial insomnia. The pathophysiology of prion diseases involves the conversion of normal cellular Prion protein from a mostly alpha-helical structure into a disease-causing form, with a beta-pleated secondary structure known as PrP scrapies. The beta-pleated form is nondegradable and engages in a cycle, causing the conversion of normally folded prion protein into a pathologic misfolded form. The pathologic form causes damage to neurons and glial cells, leading to the formation of intracellular vacuoles. The conversion itself can be sporadic, inherited, or transmitted.<xref ref-type="bibr" rid="article-28825.r5">[5]</xref>&#x000a0;The most common prion disease is Creutzfeldt-Jakob disease. The disease itself is usually sporadic but can occur due to exposure to human tissue infected with prions. Variant Creutzfeldt-Jakob disease is related to the consumption of meat from cattle, which has a prion disease known as bovine spongiform encephalopathy or mad cow disease. Fatal familial insomnia is due to an inheritance of a mutated form of prion protein and leads to severe insomnia as well as an exaggerated startle response. Kuru is a transmitted form of prion disease noted in tribal populations that practice cannibalism.<xref ref-type="bibr" rid="article-28825.r6">[6]</xref><xref ref-type="bibr" rid="article-28825.r7">[7]</xref><xref ref-type="bibr" rid="article-28825.r8">[8]</xref></p>
        <p>
<bold>Amyloidosis</bold>
</p>
        <p>Amyloidosis can be classified as systemic, involving many organ systems, or localized to a single organ. Systemic amyloidosis can further be classified as primary or secondary amyloidosis. Primary amyloidosis involves the deposition of AL amyloid derived from misfolded immunoglobulin light chains. Secondary amyloidosis involves the deposition of AA amyloid derived from misfolded serum amyloid-associated protein. Serum amyloid-associated protein is classified as an acute-phase reactant and is increased in chronic inflammatory states, such as those in neoplastic states, and Familial Mediterranean Fever. Increased protein levels can lead to its systemic deposition as AA amyloid. The clinical picture of systemic amyloidosis is widespread due to the systemic nature of the disease.<xref ref-type="bibr" rid="article-28825.r9">[9]</xref><xref ref-type="bibr" rid="article-28825.r10">[10]</xref>&#x000a0;A variety of forms of localized amyloidosis exist. One to be aware of is Alzheimer disease.&#x000a0;Alzheimer disease involves the deposition of beta-amyloid in the brain, leading to the formation of amyloid plaques. This misfolded protein is derived from Beta-amyloid precursor protein, the gene for which can be found on chromosome 21. A large proportion of patients with Down Syndrome, or trisomy 21, develop early-onset Alzheimer disease.<xref ref-type="bibr" rid="article-28825.r11">[11]</xref><xref ref-type="bibr" rid="article-28825.r12">[12]</xref></p>
        <p><bold>Sickle Cell Disease</bold>&#x000a0;</p>
        <p>As stated, a slight change in the primary structure of a protein can lead to changes in the protein&#x02019;s shape and function. Sickle-cell disease is an inherited blood disorder caused by substituting&#x000a0;1 amino acid for another. A nonpolar valine is substituted for a charged glutamic acid at the sixth amino acid position in the structure of hemoglobin- commonly referred to as an E6V mutation. Hemoglobin is the iron-containing oxygen transport protein in red blood cells, which transport oxygen from the lungs to the tissues. This protein comprises&#x000a0;4 polypeptide chains,&#x000a0;2 of which are alpha-subunits and&#x000a0;2 of which are beta-subunits. Sickle-cell hemoglobin has normal alpha-subunits, but its beta-subunits are abnormally folded. This abnormal shape leads to hydrophobic reactions that lead to aggregation into a fiber and greatly reduce the capacity for oxygen transport. Furthermore, the fibers of sickle-cell hemoglobin deform red blood cells into a sickle shape.<xref ref-type="bibr" rid="article-28825.r13">[13]</xref>&#x000a0;Pain is the most common symptom of sickle cell disease because the angular cells can clog small blood vessels, impeding blood flow. These symptoms can be reduced and sometimes avoided by drinking plenty of water, avoiding places with high altitudes, and avoiding places with low oxygen levels. Unfortunately, the symptoms of sickle-cell disease usually worsen with time. In the most extreme cases, even blindness can be caused due to a lack of oxygen in the eye. This example is a dramatic explanation of how a change in&#x000a0;1 amino acid can lead to a change in protein shape and have a devastating effect on the lives of certain individuals.<xref ref-type="bibr" rid="article-28825.r14">[14]</xref></p>
      </sec>
      <sec id="article-28825.s4">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28825&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28825">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28825/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28825">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-28825.s5">
        <title>References</title>
        <ref id="article-28825.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Janke</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kulke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Buchholz</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Geist</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Langel</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Delcea</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced activation of integrin alpha IIb beta 3 leads to minor localized structural changes.</article-title>
            <source>PLoS One</source>
            <year>2019</year>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>e0214969</fpage>
            <pub-id pub-id-type="pmid">30978226</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28825.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kappel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jarmoskaite</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Vaidyanathan</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Greenleaf</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Herschlag</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Blind tests of RNA-protein binding affinity prediction.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2019</year>
            <month>Apr</month>
            <day>23</day>
            <volume>116</volume>
            <issue>17</issue>
            <fpage>8336</fpage>
            <page-range>8336-8341</page-range>
            <pub-id pub-id-type="pmid">30962376</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28825.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Banach</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Konieczny</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Roterman</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Secondary and Supersecondary Structure of Proteins in Light of the Structure of Hydrophobic Cores.</article-title>
            <source>Methods Mol Biol</source>
            <year>2019</year>
            <volume>1958</volume>
            <fpage>347</fpage>
            <page-range>347-378</page-range>
            <pub-id pub-id-type="pmid">30945229</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28825.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shaikho</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Habara</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Alsultan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Al-Rubaish</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Al-Muhanna</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Naserullah</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Alsuliman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Qutub</surname>
                <given-names>HO</given-names>
              </name>
              <name>
                <surname>Patra</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Sebastiani</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Baltrusaitis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Farrell</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Chui</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Al-Ali</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Variants of ZBTB7A (LRF) and its &#x003b2;-globin gene cluster binding motifs in sickle cell anemia.</article-title>
            <source>Blood Cells Mol Dis</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>59</volume>
            <fpage>49</fpage>
            <page-range>49-51</page-range>
            <pub-id pub-id-type="pmid">27282567</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28825.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mays</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Soto</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The stress of prion disease.</article-title>
            <source>Brain Res</source>
            <year>2016</year>
            <month>Oct</month>
            <day>01</day>
            <volume>1648</volume>
            <issue>Pt B</issue>
            <fpage>553</fpage>
            <page-range>553-560</page-range>
            <pub-id pub-id-type="pmid">27060771</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28825.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vacca</surname>
                <given-names>VM</given-names>
              </name>
            </person-group>
            <article-title>CJD: Understanding Creutzfeldt-Jakob disease.</article-title>
            <source>Nursing</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>46</volume>
            <issue>3</issue>
            <fpage>36</fpage>
            <page-range>36-42; quiz 42-3</page-range>
            <pub-id pub-id-type="pmid">26840797</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28825.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Llorens</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zarranz</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zerr</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ferrer</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Fatal Familial Insomnia: Clinical Aspects and Molecular Alterations.</article-title>
            <source>Curr Neurol Neurosci Rep</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>30</fpage>
            <pub-id pub-id-type="pmid">28324299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28825.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liberski</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Sikorska</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Kuru: the first prion disease.</article-title>
            <source>Adv Exp Med Biol</source>
            <year>2012</year>
            <volume>724</volume>
            <fpage>143</fpage>
            <page-range>143-53</page-range>
            <pub-id pub-id-type="pmid">22411241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28825.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Desport</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bridoux</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sirac</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Delbes</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bender</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fernandez</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Quellard</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lacombe</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Goujon</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Lavergne</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Abraham</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Touchard</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fermand</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Jaccard</surname>
                <given-names>A</given-names>
              </name>
              <collab>Centre national de r&#x000e9;f&#x000e9;rence pour l&#x02019;amylose AL et les autres maladies par d&#x000e9;p&#x000f4;ts d&#x02019;immunoglobulines monoclonales</collab>
            </person-group>
            <article-title>Al amyloidosis.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2012</year>
            <month>Aug</month>
            <day>21</day>
            <volume>7</volume>
            <fpage>54</fpage>
            <pub-id pub-id-type="pmid">22909024</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28825.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Obici</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Merlini</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>AA amyloidosis: basic knowledge, unmet needs and future treatments.</article-title>
            <source>Swiss Med Wkly</source>
            <year>2012</year>
            <volume>142</volume>
            <fpage>w13580</fpage>
            <pub-id pub-id-type="pmid">22653707</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28825.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reiss</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Arain</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Stecker</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Siegart</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Kasselman</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Amyloid toxicity in Alzheimer's disease.</article-title>
            <source>Rev Neurosci</source>
            <year>2018</year>
            <month>Aug</month>
            <day>28</day>
            <volume>29</volume>
            <issue>6</issue>
            <fpage>613</fpage>
            <page-range>613-627</page-range>
            <pub-id pub-id-type="pmid">29447116</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28825.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wiseman</surname>
                <given-names>FK</given-names>
              </name>
              <name>
                <surname>Pulford</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Barkus</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Portelius</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Webb</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ch&#x000e1;vez-Guti&#x000e9;rrez</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cleverley</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Noy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sheppard</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sarell</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Rickman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Choong</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Tosh</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Siganporia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Whittaker</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Szaruga</surname>
                <given-names>M</given-names>
              </name>
              <collab>London Down syndrome consortium</collab>
              <name>
                <surname>Murphy</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Blennow</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>de Strooper</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zetterberg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bannerman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Holtzman</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Tybulewicz</surname>
                <given-names>VLJ</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>EMC</given-names>
              </name>
              <collab>LonDownS Consortium</collab>
            </person-group>
            <article-title>Trisomy of human chromosome 21 enhances amyloid-&#x003b2; deposition independently of an extra copy of APP.</article-title>
            <source>Brain</source>
            <year>2018</year>
            <month>Aug</month>
            <day>01</day>
            <volume>141</volume>
            <issue>8</issue>
            <fpage>2457</fpage>
            <page-range>2457-2474</page-range>
            <pub-id pub-id-type="pmid">29945247</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28825.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Snyder</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Theodore</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Quarmyne</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Eckman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lane</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Improving an Administrative Case Definition for Longitudinal Surveillance of Sickle Cell Disease.</article-title>
            <source>Public Health Rep</source>
            <year>2019</year>
            <season>May/Jun</season>
            <volume>134</volume>
            <issue>3</issue>
            <fpage>274</fpage>
            <page-range>274-281</page-range>
            <pub-id pub-id-type="pmid">30970223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28825.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Badior</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Molecular mechanism for the red blood cell senescence clock.</article-title>
            <source>IUBMB Life</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>70</volume>
            <issue>1</issue>
            <fpage>32</fpage>
            <page-range>32-40</page-range>
            <pub-id pub-id-type="pmid">29240292</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
